AUTHORS
Chang Zhang, PhD, Sixia Huang, MD-PhD2, Kohei Kume, PhD3, Zhangliang Cheng, BSc4, Ruifeng Sun, BS5, Mark E Robinson, PhD6, Ruoyi Shi7, Stephen Martindale, BA8, Jing Wang, PhD9, Matthew S Davids, MD, MMSc10, Hiromi Sesaki, PhD11, David C Chan, MD-PhD12, Markus Müschen, MD-PhD13
AFFILIATIONS
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
3 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Immunobiology, New Haven, Connecticut, United States
6 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
7 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
8 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
9 Department of Medical Oncology, Boston, Massachusetts, United States
10 Department of Medical Oncology, Boston, Massachusetts, United States
11 Department of Cell Biology, Baltimore, Maryland, United States
12 Division of Biology, Pasadena, California, United States
13 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
ABSTRACT
Background. Compared to other cell types with hundreds of mitochondria per cell, B-lymphocytes function with the smallest mitochondrial pool among all somatic cell types. Despite the limitation of only 2-6 mitochondria per cell, activated B-cells sustain rapid proliferation and transformed B-cells exhibit faster proliferation rates than solid tumors. How B-cells reconcile low mitochondrial abundance with these demands remains unclear. We hypothesized that mitofusin-dependent network formation preserves mitochondrial function as mitochondrial number declines, creating a therapeutically actionable vulnerability in B-cell malignancies.
Methods. Mitochondrial architecture and B-cell development were examined by live-cell imaging and flow cytometry in mice with stage-specific deletion of Mfn1/Mfn2 or the fission factor Drp1. Mitofusin dependency and lineage specificity were evaluated using inducible gene deletion and CRISPR-Cas9 editing in murine and human B-cell acute lymphoblastic leukemia (B-ALL), B-cell lymphoma, myeloid leukemia, and C/EBPα-reprogrammed models. Metabolic and Ca²⁺-signaling consequences were assessed by Seahorse analysis, metabolomics, compartment-specific Ca²⁺ sensors, and optogenetic CRAC-channel activation. Venetoclax responses were evaluated by apoptosis assays, dynamic BH3 profiling, and Zero Interaction Potency (ZIP) synergy analysis.
Results. During B-lymphopoiesis, mitochondrial number declined from ~40 per cell in early progenitors to ~5 in small pre-B cells. Concurrent increases in mitochondrial length, aspect ratio, and area reflected a transition from fragmented organelles to interconnected tubular networks. This remodeling coincided with rapid proliferation, suggesting that network connectivity compensates for declining mitochondrial abundance. Combined Mfn1/Mfn2 loss prevented network formation, blocked development at the pre-B-cell receptor checkpoint, and impaired plasma cell differentiation, antibody production, and affinity maturation. In contrast, Drp1 deletion induced premature mitochondrial elongation without compromising B-cell development or activation, demonstrating a specific requirement for fusion rather than mitochondrial morphology alone.
This dependency persisted after malignant transformation. Inducible Mfn1/Mfn2 deletion in BCR-ABL1-transformed murine B-ALL cells nearly abolished colony formation, induced cell-cycle arrest, and rapidly induced cell death. Mitofusin dependency extended to NRAS-G12D-driven murine B-ALL, patient-derived B-ALL, and B-cell lymphoma. Conversely, CML and AML cells were resistant. C/EBPα-mediated conversion of B-ALL cells toward a myeloid-like state also rescued mitofusin dependence, establishing fusion as a lineage- rather than oncogene-defined vulnerability.
Mechanistically, loss of mitochondrial fusion impaired oxidative phosphorylation, tricarboxylic acid-cycle activity, and de novo pyrimidine biosynthesis. Restoration of dihydroorotate dehydrogenase (DHODH) activity partially rescued mitofusin-deficient cells, identifying DHODH-dependent pyrimidine synthesis as a critical downstream effector. Mitofusin loss also disrupted endoplasmic reticulum-mitochondrial Ca²⁺ coupling and converted coordinated Ca²⁺ responses into aberrant high-frequency, low-amplitude oscillations. Optogenetic enforcement of high-frequency Ca²⁺ oscillations compromised B-ALL survival, linking altered Ca²⁺ dynamics to the cytotoxic effects of impaired fusion.
Genetic and pharmacologic disruption of mitochondrial fusion enhanced venetoclax sensitivity. The mitofusin inhibitor MFI8 increased apoptotic priming and selectively potentiated venetoclax-induced apoptosis in B-ALL and B-cell lymphoma, with weaker effects in myeloid leukemia. MFI8 and venetoclax were synergistic in treatment-naïve B-cell lymphoma models, and synergy was retained in venetoclax-resistant mantle cell lymphoma derivatives.
Conclusions. B-lineage cells compensate for mitochondrial depletion by organizing the remaining organelles into mitofusin-dependent networks. This architecture sustains oxidative metabolism, DHODH-dependent pyrimidine synthesis, ER-mitochondrial Ca²⁺ homeostasis, and resistance to apoptosis. These findings identify mitochondrial fusion as a lineage-specific vulnerability and support combining mitofusin inhibitors with venetoclax to enhance responses and overcome acquired resistance in B-cell malignancies.
DISCLOSURES
Ruifeng Sun, BS: No relevant conflicts of interest to declare.